Inozyme Pharma Q1 net loss $23.3M ($0.38/sh); cash $166.2M; positive ABCC6 data

Inozyme Pharma, Inc.

2024-Q1 EPS reported -$0.38

Net loss $23.3M ($0.38 loss per share) vs $17.4M ($0.40) year ago.
Cash, cash equivalents, and short-term investments $166.2M as of March 31, 2024; expected to fund operations into Q4 2025.
Positive topline safety, immunogenicity, and clinical improvement data for INZ-701 in adults with ABCC6 Deficiency reported in April 2024.
Plan to initiate pivotal trial in pediatric ABCC6 Deficiency in Q1 2025, subject to regulatory review and funding.
Interim data from SEAPORT-1 (calciphylaxis) on track for Q4 2024; ENERGY-1 (ENPP1 infants) interim data expected 2H 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Inozyme Pharma, Inc. reported the first quarter ended March 31, 2024 results: net income $23.3 million, EPS $0.38 loss per share.

Period: the first quarter ended March 31, 2024
Net income: $23.3 million
EPS: $0.38 loss per share
Result: reported results

Exact text from the filing

Net loss was $23.3 million, or $0.38 loss per share, for the quarter ended March 31, 2024

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-053979

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.